A phase I/II trial of the combination 5-azacitidine and gemtuzumab ozogamicin therapy for treatment of relapsed AML [acute myeloid leukaemia].

Trial Profile

A phase I/II trial of the combination 5-azacitidine and gemtuzumab ozogamicin therapy for treatment of relapsed AML [acute myeloid leukaemia].

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Azacitidine (Primary) ; Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 25 Oct 2016 Planned End Date changed from 1 Feb 2015 to 1 Jun 2017.
    • 25 Oct 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top